Résumé
Face à l’augmentation dramatique du nombre de patients touchés par la maladie d’Alzheimer, de nombreuses voies de recherche, médicamenteuses ou non, se sont développées au cours des 20 dernières années. Certaines ont abouti à la commercialisation de traitements médicamenteux symptomatiques comme les anticholinestérasiques ou la mémantine. Leur intérêt, leurs limites comme leurs modalités de prescription doivent être bien connus des praticiens, qu’ils en soient les initiateurs ou non. Les thérapies d’avenir explorent des voies curatives intervenant directement sur les lésions cérébrales et des pistes préventives afin d’éviter l’apparition de la maladie chez les sujets à risque. Parallèlement et de façon complémentaire aux traitements médicamenteux, différentes modalités d’interventions non pharmacologiques, individuelles ou collectives, ont émergé. Deux grandes orientations d’intervention sont bien définies à partir de cadrages théoriques différents, de type « rééducation » et « stimulation ». Plus récemment, se sont développées des modalités de prise en charge de type « activité physique ». L’apport de ces prises en charge fait également l’objet d’évaluations rigoureuses.
Abstract
As the number of patients suffering from Alzheimer’s disease has dramatically increased, numerous research projects have been developed during the last 20 years. Some clinical trials have led to the marketing of symptomatic therapies such as anticholinesterasic drugs or memantine. Practitioners must be very familiar with their effects, their limits and the rules concerning their prescription, whether or not they initiate treatment themselves. Research into future therapies explores curative methods, which operate directly on the cerebral lesions, as well as ways of preventing the occurrence of the disease in subjects at risk. In parallel with and in complement to drug therapies, various methods of non-pharmacological, individual or collective interventions, have emerged. Two main kinds of intervention have been well defined, each within a different theoretical framework, involving “rehabilitation” and “stimulation”. More recently, interventions based on “physical activity” have been developed. The impact of these non-pharmacological interventions is currently being evaluated.
Références
AD2000 Collaborative Group (2004) Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomised double-blind trial. Lancet 363: 2105–2115 (correspondence in Lancet 2004; 364: 1213–6)
Ancoli-Israël S, Martin JL, Kripke DF, et al. (2002) Effect of light treatment on sleep and circadian rhythms in demented nursing home patients. J Am Geriatr Soc 50: 282–289
Auriacombe S, Pere JJ, Rivage Study Group (2003) No donepezil discontinuation effect in patients with Alzheimer’s disease who were switched to rivastigmine after failing to benefit from donepezil treatment. Curr Med Res Opin 18: 715–717
Adam S, Van Der Linden M, Juillerat AC, et al. (2000) The cognitive management of daily life activities in patients with mild to moderate Alzheimer’s disease in a day care center: a case report. Neuropsychological rehabilitation 10(05): 485–509
Brodaty H, Green A, Koschera A (2003) Meta-analysis of psychosocial interventions for caregivers of people with dementia. J Am Geriatric Soc 51: 657–664
Brotons M, Kroger SM (2000) The impact of music therapy on language functionning in dementia. J Music Ther 37(3): 183–195
Bullock R, Touchon J, Bergman H, et al. (2005) Riverstigmine and donepezil treatment in moderate to moderately-severe Alzheimer’s disease over a 2-year period. Curr Med Res Opin 21: 1317–1327
Clare L, Woods RT, Moniz Cook ED, et al. (2003) Cognitive rehabilitation and cognitive training for early-stage Alzheimer’s disease and vascular dementia. Cochrane Database Syst Rev 4: CD003260
Cooke DD, McNally L, Mulligan KT, et al. (2001) Psychosocial interventions for caregivers of people with dementia: a systematic review. Aging Ment Health 5(2): 120–135
De Rotrou J (2008) Stimulation cognitive et vieillissement. In: Gérontologie préventive. Abrégés de médecine. Masson (sous presse)
Garcia de la Rocha ML, Frank A, Galiano M, et al. (2004) Benefits of cognitive-motor intervention in MCI and mild to moderate Alzheimer’s disease. Neurology 63(12): 2348–2353
Gasio PF, Krauchi K, Cajochen C, et al. (2003) Dawn-dusk simulation light therapy of disturbed circadian rest-activity cycles in demented elderly. Exp Gerontol 38: 207–216
Gauthier SG (2005) Realizing early treatment benefits in dementia. Eur J Neurol. 12(Suppl. 3): 11–16
Geldmacher DS, Provenzano G, McRaae T, et al. (2003) Donezepil is associated with delayed nursing home placement in patients with Alzheimer’s disease. J Am Geriatr Soc 51(7): 937–944
Gildman S, Koller M, Back R, et al. (2003) Clinical effects of Aβ immunization (AN1792) in patients with Alzheimer’s disease in an interrupted trial. Neurology 61: 46–54
Hanon O, Forette F (2004) Prevention of dementia: lessons form Syst-Eur and Progress. J Neurol Sci 226: 71–74
Holmes C, Wilkinson D, Dean C, et al. (2004) The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer’s disease. Neurology 63(2): 214–219
Howard RJ, Juszczak E, Ballard CG, et al., for the CALM-AD trial group 2007. Donepezil for the treatment of agitation in Alzheimer’s disease. N Engl J Med 357: 1382–1392
Mohs RC, Doody RS, Morris JR, et al. (2001) A 1-year placebo-controlled preservation of function survival study of donezepil in AD patients. Neurology 57(3): 481–488
Nunez M, Hasselbach S, Heun R, et al. (2003) Donepezil-treated Alzheimer’s disease patients with apparent initial cognitive decline demonstrate significant benefits when therapy is continued: results from a randomized, placebocontrolled trial; Second Annual Dementia Congress, September 24–14th, Washington DC, USA
Ritchie CW, Ames D, Clayton T (2004) Metaanalysis of randomized trials of the efficacy and safety of donepezil, galanthamine and rivastigmine for the treatment of Alzheimer’s disease. Am J Geriatr Psychiatry 12: 358–369
Rousseau T (1998) Thérapie cognitivocomportementale des troubles de la communication dans la démence de type alzheimer. Rev Fr Psychiatrie Psychol Med 20: 88–90
Tariot P, Farlow M, Grossberg G, et al. (2004) Memantine treatment in patients with moderate to severe Alzheimer’s disease already receiving donezepil. JAMA 291: 317–324
Thorgrimsen L, Spector A, Wiles A, et al. (2003) Aroma therapy for dementia. Cochrane Database Syst Rev 3: CD003150
Vink AC, Birks JS, Bruinsma MS, et al. (2004) Music therapy for people with dementia. Cochrane Database Syst Rev 3: CD003477
Wilkinson DG, Passmore AP, Bullock R, et al. (2002) Étude multinationale, randomisée, de 12 semaines, comparant le donepezil et la rivastigmine chez de patients atteints de la maladie d’Alzheimer d’intensité légère à modérée. Int J Clin Pract 56: 441–446
Winblad B, Engelad K, Soinen H, et al. (2001) A 1-year randomized placebo-controlled study of donezepil in patients with mild moderate Alzheimer’s disease. Neurology 57: 489–495
Winblad B, Kilander L, Eriksson S, et al. (2006) Donepezil in patients with severe Alzheimer’s disease: double-blind, parallel-group, placebo-controlled study. Lancet 368: 1507–1565 (Errata, Lancet 2006; 367: 1980, 2006; 368: 1650)
Winblad B, Jones RW, With Y, et al. (2007) Memantine in moderate to severe Alzheimer’s disease: a meta-analysis of randomised clinical trials. Dement Geriatr Cogn Disord 24: 20–27
Woods B, Thorgrimsen L, Spector A, et al. (2006) Improved quality of life and cognitive stimulation therapy in dementia. Aging Ment Health 10(3): 219–226
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Seux, M.L., de Rotrou, J. & Rigaud, A.S. Les traitements de la maladie d’Alzheimer. Psychiatr Sci Hum Neurosci 6, 82–90 (2008). https://doi.org/10.1007/s11836-008-0060-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11836-008-0060-4
Mots clés
- Maladie d’Alzheimer
- Traitement anticholinestérasique
- Traitement antiglutaminergique
- Stimulation cognitive
- Interventions psychosociales